Last reviewed · How we verify
NCT03310918
A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy
NA trial testing Palliative Care in Acute Myeloid Leukemia in 320 participants. Participants enrolled and being followed up; not accepting new ones.
1 April 2023
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 320 |
| Start date | 31 October 2017 |
| Primary completion | 1 April 2023 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Palliative Care — full drug profile →
- Standard Leukemia care
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
- Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
Sponsor
Massachusetts General Hospital
Who can join
18 and older, any sex, with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is evaluating the impact a collaborative palliative care and oncology team will have on end-of-life outcomes, quality of end-of-life care, and the quality of life, symptoms, and mood of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Palliative and End-of-Life Care for Patients With Hematologic Malignancies.
El-Jawahri A, Nelson AM, Gray TF, Lee SJ, et al · · 2020 · cited 143× · PMID 32023164 · DOI 10.1200/jco.18.02386 -
The effectiveness and cost-effectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers.
Bajwah S, Oluyase AO, Yi D, Gao W, et al · · 2020 · cited 133× · PMID 32996586 · DOI 10.1002/14651858.cd012780.pub2 -
Code status transitions in patients with high-risk acute myeloid leukemia.
Abrams HR, Nipp RD, Traeger L, Lavoie MW, et al · · 2022 · cited 3× · PMID 35537113 · DOI 10.1182/bloodadvances.2022007009 -
Trajectories of physical well-being among adults with acute myeloid leukemia.
Jensen-Battaglia M, Sohn MB, Consagra W, Wang Y, et al · · 2024 · cited 1× · PMID 38429079 · DOI 10.1182/bloodadvances.2023011804 -
Challenges in hospice and end-of-life care in the transfusion-dependent patient.
Rodenbach R, Caprio T, Loh KP. · · 2024 · PMID 39644067 · DOI 10.1182/hematology.2024000560
Verify or expand the search:
- PubMed search for NCT03310918
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Palliative Care
Trials testing the same drug.
- NCT06146738 — The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) · recruiting
- NCT05646576 — Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy · NA · recruiting
- NCT04248244 — Effects of Early Palliative Care Integration on Patients With Newly Diagnosed Multiple Myeloma · NA · completed
- NCT03540771 — Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD) · NA · completed
- NCT03471546 — Early Palliative Care Intervention in Malignant Glioma · NA · completed
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03310918 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03310918.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing